Oxycodone CR

DRUG8 trials

Conditions

ArthritisCancer Related PainHealthyJoint DiseasesLow Back PainLower Back PainModerate to Severe Chronic Pain Due to Osteoarthritis of the KneeOsteoarthritis

Phase 2

Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee

CompletedNCT00979953

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Osteoarthritis of the Knee

Start: 2009-10-31End: 2010-06-30Updated: 2015-08-14

Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

CompletedNCT01709214

Tris Pharma, Inc.Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

Start: 2012-12-04End: 2014-04-04Updated: 2021-07-15

Phase 3

A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain

CompletedNCT00361504

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Lower Back Pain, Osteoarthritis, Hip, Osteoarthritis, Knee +1

Start: 2006-11-30End: 2008-07-31Updated: 2014-04-29

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain

CompletedNCT00449176

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Low Back Pain

Start: 2007-02-28End: 2008-05-31Updated: 2012-04-30

A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease

CompletedNCT00784277

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Arthritis, Joint Diseases, Osteoarthritis

Start: 2008-10-31End: 2009-07-31Updated: 2012-02-13

A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain

CompletedNCT01165281

Janssen Research & Development, LLCPain

Start: 2010-08-31End: 2012-08-31Updated: 2017-07-21

NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers

NCT04808531

Medlab ClinicalCancer Related Pain

Start: 2023-11-30End: 2024-06-30Target: 360Updated: 2022-04-12

Phase 4

Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)

CompletedNCT00955110

Endo PharmaceuticalsHealthy

Start: 2009-06-30End: 2009-09-30Updated: 2017-10-05

Related Papers

Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial.

2015-10-0134 citations

Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain.

2015-09-0124 citations

Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysis.

2014-08-0113 citations

A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain.

2013-09-015 citations

Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain.

2013-08-2356 citations

Efficacy of tapentadol ER for managing moderate to severe chronic pain.

2013-01-0141 citations

Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain.

2010-09-01127 citations